Skip to main content

NCT01281839 - A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Hepatitis C, Genotype 1 I

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects Who Relapsed After Previous Interferon-based Therapy


Data Specification

Not Available


Annotated CRF

Not Available

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Simeprevir
Product Name
OLYSIO®
Therapeutic Area
Viral Diseases
Enrollment
394
% Female
34.4%
% White
94.4%
Product Class
Antiviral Agent
Sponsor Protocol Number
TMC435HPC3007
Data Holder
Johnson & Johnson
Condition Studied
Hepatitis C
Mean/Median Age (Years)
52.0

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Collected Datasets
Data Definition Specification
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.